KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine test for Bladder Cancer

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ --KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17 Bladder Cancer Recurrence Test.